预约演示
更新于：2026-01-06
Nemonoxacin Malate
苹果酸奈诺沙星
更新于：2026-01-06
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2016-05-27), |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C24H31N3O9 |
InChIKeyYMVJINCWEIPOFL-FXMYHANSSA-N |
CAS号951163-60-3 |
关联
21
项与 苹果酸奈诺沙星 相关的临床试验CTR20254173
苹果酸奈诺沙星胶囊人体生物等效性研究
ChiCTR2300075207
The Observational Study on the Safety and Efficacy of Nemonoxacin Malate and Sodium Chloride Injection in the Treatment of Adult Lower Respiratory Tract Infection Patients
CTR20231866
评价苹果酸奈诺沙星胶囊治疗单纯性尿路感染的有效性与安全性的多中心、随机、双盲、左氧氟沙星平行对照的Ⅲ期临床研究
100 项与 苹果酸奈诺沙星 相关的临床结果
登录后查看更多信息
100 项与 苹果酸奈诺沙星 相关的转化医学
登录后查看更多信息
100 项与 苹果酸奈诺沙星 相关的专利（医药）
登录后查看更多信息
78
项与 苹果酸奈诺沙星 相关的文献（医药）2025-10-03JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones
Article
作者: Xue, Jiaoyu ; Jiang, Tingfei ; Zhang, Mingrui ; Shi, Dongyan ; Yang, Jing
Abstract:
Objectives:
To establish patterns of the antimicrobial susceptibility of Nocardia species to carbapenems and fluoroquinolones and analysis of phenotypic–genotypic correlations.
Methods:
Isolates were identified to the species using 16S rRNA, secA1, or rpoB gene sequencing analysis. The antimicrobial susceptibility testing was performed using the broth microdilution method, and WGS was employed to analyse the presence of resistance genes and/or mutations of Nocardia species against carbapenems and fluoroquinolones.
Results:
Among 143 Nocardia isolates, N. farcinica (27.27%, 39/143) and N. cyriacigeorgica (25.17%, 36/143) were the most common species, followed by N. abscessus Complex (18.88%, 27/143). The MIC90s of the seven carbapenems were 8 mg/L for doripenem, 8 mg/L for meropenem, 16 mg/L for ertapenem, 16 mg/L for biapenem, 64 mg/L for imipenem, 64 mg/L for faropenem and 128 mg/L for tebipenem, respectively. The susceptibility rates to imipenem were 76.9% and 88.9% for N. farcinica and N. cyriacigeorgica, respectively, but only 14.3% and 0% for N. otitidiscavarium and N. brasiliensis, respectively. Further, 90% of N. brasiliensis and 50% of N. otitidiscaviarum isolates were susceptible and intermediate to meropenem. WGS identified blaFAR-1 gene in N. farcinica and blaAST-1 gene in N. cyriacigeorgica, respectively. The MIC90s of the four fluoroquinolones were 1 mg/L for sitafloxacin, 4 mg/L for nemonoxacin, 4 mg/L for moxifloxacin and 16 mg/L for ciprofloxacin, respectively. The susceptibility rate of Nocardia species to ciprofloxacin was low except for N. farcinica. The resistance to fluoroquinolones arise from mutations in the gyrA gene.
Conclusions:
Nocardia spp. exhibited varying patterns of susceptibility to carbapenems and fluoroquinolones respectively. Importantly, different Nocardia spp. exhibited different patterns of susceptibility to carbapenems and fluoroquinolones, respectively.
2025-09-23Cureus Journal of Medical Science
Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials
作者: Khan, Alina S ; Muhammad, Alina A ; Ahmed, Komal F ; Varrassi, Giustino ; Khatri, Mahima ; Lodhi, Muniba F ; Mazhar, Fariha ; Kumar, Satesh ; Iqbal, Arham
[This corrects the article DOI: 10.7759/cureus.37650.].
2025-07-01AMERICAN FAMILY PHYSICIAN
Top 20 Research Studies of 2024 for Primary Care Physicians.
Review
作者: Ebell, Mark H ; Grad, Roland
This article summarizes the top 20 research studies of 2024 identified as POEMs (patient-oriented evidence that matters). Based on a network meta-analysis, the oral antibiotics most likely to be effective for community-acquired pneumonia are telithromycin (not available in the United States), azithromycin, amoxicillin-clavulanate, and the quinolones levofloxacin and nemonoxacin (not available in the United States). The oral antivirals molnupiravir and nirmatrelvir-ritonavir reduce hospitalizations in immunocompromised patients with COVID-19. In average-risk infants, a single dose of nirsevimab reduces hospitalizations due to respiratory syncytial virus. Amoxicillin with or without clavulanate is more effective than placebo for children with symptoms of acute sinusitis. Benzyl benzoate 25% is highly effective for scabies in adolescents and adults. Lactobacillus-containing probiotics reduce the incidence of recurrent urinary tract infections (UTIs) in premenopausal women with frequent UTIs. Low-dose amitriptyline is effective as second-line therapy for irritable bowel syndrome. For patients with uncomplicated gallstones, conservative management is a reasonable option. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are better than older drugs at improving patient-oriented outcomes for type 2 diabetes. Continuous or intermittent glucose monitoring is minimally effective for control of type 2 diabetes and can be harmful. Phentermine-topiramate and GLP-1 receptor agonists are the most effective drugs for promoting weight loss. Semaglutide is effective for secondary prevention of cardiovascular disease in people with obesity and no diabetes. SGLT-2 inhibitors and GLP-1 receptor agonists decrease cardiovascular death in older adults with type 2 diabetes and heart failure. Beta blockers do not prevent subsequent events after myocardial infarction in patients with preserved ejection fraction. For patients who do not quit smoking after a trial of varenicline or combined nicotine replacement therapy, a higher dose of either drug can increase quit rates. e-Cigarettes increase abstinence from smoking, but long-term vaping is a consequence for some. Oral naltrexone and acamprosate are safe and effective treatments for alcohol use disorder. Cognitive behavior therapy can reduce fatigue attributed to long COVID. New monoclonal antibodies for Alzheimer disease are harmful, expensive, and minimally effective. Clinicians may choose to deliver bad news in person or by telephone, using their judgment or patient preference to decide which is best for the patient.
100 项与 苹果酸奈诺沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社区获得性肺炎 | 中国 | 2016-05-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 感染 | 申请上市 | 俄罗斯 | 2022-01-30 | |
| 泌尿道感染 | 临床3期 | 中国 | 2023-08-29 | |
| 细菌性肺炎 | 临床3期 | 俄罗斯 | 2016-05-04 | |
| 糖尿病足感染 | 临床2期 | 美国 | 2008-06-01 | |
| 糖尿病足感染 | 临床2期 | 南非 | 2008-06-01 | |
| 糖尿病足感染 | 临床2期 | 中国台湾 | 2008-06-01 | |
| 糖尿病足感染 | 临床2期 | 泰国 | 2008-06-01 | |
| 功能障碍 | 临床1期 | 中国 | 2017-04-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 342 | Placebo (100 ml)+Nemonoxacin (Nemonoxacin) | 鬱淵鑰鏇顧範觸襯壓鑰: Difference in percentage = 6.1 (95% CI, -0.7 ~ 13.0); Odds Ratio (OR) = 1.45 (95% CI, 0.49 ~ 4.29), P-Value = 0.499 更多 | - | 2023-02-16 | ||
Placebo (250 ml)+Tavanic (Tavanic®) | |||||||
临床1期 | 10 | (Moderate Hepatic Impairment Group) | 鬱遞築構餘憲繭選簾獵(膚範齋鹹襯廠廠鹹窪襯) = 構鬱積蓋鹽獵窪膚壓襯 繭繭衊顧夢膚鑰遞觸願 (獵繭簾鑰獵築膚淵獵襯, (17.30)) | - | 2019-03-01 | ||
(Healthy Control Group) | 鬱遞築構餘憲繭選簾獵(膚範齋鹹襯廠廠鹹窪襯) = 觸淵構憲壓鑰顧糧齋觸 繭繭衊顧夢膚鑰遞觸願 (獵繭簾鑰獵築膚淵獵襯, (10.16)) | ||||||
临床3期 | 527 | 範憲襯選糧鹽觸鹹襯醖(艱積製繭選淵願衊鏇選) = The incidence of adverse events (AEs) was comparable between nemonoxacin (33.1%, 118/356) and levofloxacin (33.3%, 57/171) 範積範鬱鹽醖糧獵願願 (鬱繭壓觸簾鏇網衊壓製 ) | 积极 | 2019-02-01 | |||
临床2期 | 192 | 淵醖醖鬱衊鬱鬱築鑰築(繭鹽襯餘鬱簾淵蓋衊夢) = Most drug-related adverse events were mild and transient, mainly gastrointestinal symptoms such as nausea and vomiting, transient neutropenia, and elevated liver enzymes 廠簾膚鑰餘鬱襯齋廠廠 (襯廠製鹹艱鹽觸鬱築淵 ) 更多 | 积极 | 2017-12-01 | |||
临床2期 | - | 207 | 繭廠鏇醖壓糧製積繭積(窪繭衊選築醖願製鏇襯) = 築選淵壓鏇觸顧艱夢簾 築憲餘衊襯繭齋壓廠獵 (齋夢鏇顧積壓觸壓艱餘 ) 更多 | - | 2015-03-01 | ||
繭廠鏇醖壓糧製積繭積(窪繭衊選築醖願製鏇襯) = 膚廠襯築憲鬱憲觸鏇壓 築憲餘衊襯繭齋壓廠獵 (齋夢鏇顧積壓觸壓艱餘 ) 更多 | |||||||
临床2期 | 207 | (Nemonoxacin 500 mg) | 築膚繭顧製憲餘鏇壓觸 = 糧簾膚膚獵廠憲壓顧鑰 網簾壓觸餘淵鏇襯膚廠 (築願願壓鑰鑰廠積廠簾, 鹹顧繭鹹憲鹽壓繭壓選 ~ 艱鬱願夢鹽廠獵繭淵網) 更多 | - | 2015-02-18 | ||
(Nemonoxacin 650 mg) | 築膚繭顧製憲餘鏇壓觸 = 窪顧獵網衊餘鬱製壓製 網簾壓觸餘淵鏇襯膚廠 (築願願壓鑰鑰廠積廠簾, 鹽鬱艱網夢鏇鬱壓選遞 ~ 壓鬱鬱窪窪簾簾鹹憲膚) 更多 | ||||||
临床2期 | - | 92 | 繭餘鹹艱製壓顧獵製選(鑰齋範壓醖齋艱構襯餘) = 憲鹽蓋繭鑰壓醖積膚窪 製鏇鹽夢選鑰壓襯願範 (鹽網觸選願襯餘願選膚 ) 更多 | - | 2014-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用